

10/823,107

**Remarks**

Claims 1-4, 13-17, 31, 33, 36-38, 45, 46, 51, 52, 57, 58, and 77-82 have been allowed. In the notice of allowance, the Examiner made an amendment whereby she changed the reference of a "3- to 8-"membered partially or fully saturated heterocycle to a "3- to 6-"membered partially or fully saturated heterocycle in Claims 1, 2, 45 and 78. The basis of this change was mistakenly based on the specification on page 4, lines 1-6. Unlike the elements changed in the Claims 1, 2, 45 and 78, the definition on page 4, lines 1-6 refers to the definition of R<sup>1a</sup> and not R<sup>4</sup>. The original definitions in Claims 1, 2, 45 and 78 were supported in the specification on page 4, line 15, as well as the originally filed claims. Therefore, the amendments to Claims 1, 2, 45 and 78 with respect to the replacement of "3- to 8-" should be deleted from the Examiner's amendment and the original definition be reinstated.

With respect to the Examiner's reference to page 12, lines 3-7, the definition section specifically states "unless specified otherwise". Since the definition for R<sup>4</sup> on page 4 specifically states the range of ring sizes claimed, no reliance on the definition of heterocyclic ring is needed.

Respectfully Submitted:

Date:

March 13, 2006

Arlene K. Musser  
Attorney for Applicant  
Registration No. 37,895

Pfizer Inc.  
Patent Department, Box 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 715-0871